Virtual Library
Start Your Search
Jennifer Macphee
Author of
-
+
P2.10 - Prevention and Tobacco Control (Not CME Accredited Session) (ID 959)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.10-03 - Feasibility and Acceptability of E-Cigarettes as an Aid to Quitting Smoking in Lung Cancer Patients: A Pilot Study (ID 13193)
16:45 - 18:00 | Author(s): Jennifer Macphee
- Abstract
Background
Many patients diagnosed with lung cancer continue to smoke even though this can make treatment less effective and increase side effects. E-cigarettes form part of the UK’s tobacco harm reduction policy landscape and are smokers’ most popular quit attempt method. This pilot study explores feasibility and acceptability of e-cigarettes to aid smoking cessation among lung cancer patients with advanced disease undergoing chemotherapy.
mokers with Stage IV lung cancer were recruited in NHS Greater Glasgow and Clyde and NHS Lanarkshire. Participants were provided with a 2nd generation e-cigarette device and a four week supply of e-liquid. Abaseline home visit was conducted by a researcher and an experienced e-cigarette user. Participants were followed-up over 16 weeks. We explored participants' experiences of using e-cigarettes including CO validated smoking cessation at 4 and 16 weeks. Qualitative interviews were conducted with participants (n=13), their significant others (n=6) and health professionals (n=8) engaged with lung cancer patients to obtain their views on the study.
Twenty-nine patients were recruited and completed baseline data collection. Three patients died during the study. Of the 26 remaining, 35% (n=9) were CO validated as having stopped smoking at four weeks and 15% (n=4) at 16 weeks. Study procedures were viewed as feasible and acceptable. Patients’ experiences of using e-cigarettes were mixed. Some felt unwell during treatment making stopping smoking more challenging. Those who managed to quit were very positive about e-cigarettes as were their significant others. Health professionals expressed concern about longer term e-cigarette safety but welcomed the study.
Smoking cessation should be offered to patients who have incurable disease. It is feasible and acceptable to offer e-cigarettes for smoking cessation to lung cancer patients during treatment. Cessation outcomes were positive and comparable with local cessation services. Future research involving a pilot randomised controlled trial is warranted but should include patients with less advanced cancer and assessment of longer term outcomes
6f8b794f3246b0c1e1780bb4d4d5dc53